PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.
PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.
| Position ? | Drug ? | Relevance ? |
Strength of Evidence ? |
||
|---|---|---|---|---|---|
Download a summary of all Clinical Annotations available.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.
The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.
The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.
Links in the "Drugs" column lead to PharmGKB Drug Pages.
|
Variant?
(build 132) |
Alternate Names ? | Drugs ? | Alleles ? | Function ? |
Amino Acid?
Translation |
|
|---|---|---|---|---|---|---|
| rs1045642 | ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, g.208920T>A, g.208920T>C, g.208920T>G, g.25171488A>C, g.25171488A>G, g.25171488A>T, mRNA 3853C>T, p.Ile1145Met | A > T/G | Not Available | Ile1145Ile | ||
| rs1128503 | ABCB1 1236C>T, ABCB1*8, ABCB1: c.1236T>C, ABCB1:1236C>T, ABCB1:1236T>C, Gly412Gly, c.1236T>A, c.1236T>C, c.1236T>G, g.167964T>A, g.167964T>C, g.167964T>G, g.25212444A>C, g.25212444A>G, g.25212444A>T, mRNA 1654T>C, p.Gly412Gly | A > G | Not Available | Gly412Gly | ||
| rs1186745 | A/C | Not Available | ||||
| rs1186746 | C/T | Not Available | ||||
| rs2032582 | 2677A, 2677G, 2677T, 3095G>T/A, 893 Ala, 893 Ser, 893 Thr, ABCB1*7, ABCB1: 2677G>T/A, ABCB1: 2677T/A>G, ABCB1: A893S, ABCB1: G2677T/A, ABCB1: c.2677G>T/A, ABCB1:2677G>A/T, ABCB1:2677G>T/A, ABCB1:A893T, Ala893Ser/Thr, MDR1, MDR1 G2677T/A, c.2677T>A, c.2677T>G, g.186947T>A, g.186947T>G, g.25193461A>C, g.25193461A>T, mRNA 3095G>T/A, p.Ala893Ser/Thr, p.Ser893Ala, p.Ser893Thr | A > T/C | Missense | Ser893Thr/Ala | ||
| rs2032583 | G/A | Not Available | ||||
| rs2229107 | ABCB: S1141T, c.3421T>A, g.208906T>A, g.25171502A>T, p.Ser1141Thr | A > T | Missense | Ser1141Thr | ||
| rs2229109 | ABCB1: c.1199G>A, c.1199G>A, c.1199G>C, c.1199G>T, g.167756G>A, g.167756G>C, g.167756G>T, g.25212652C>A, g.25212652C>G, g.25212652C>T, mRNA 1617G>A, p.Ser400Asn, p.Ser400Ile, p.Ser400Thr | C > T/A | Missense | Ser400Asn/Ile | ||
| rs2235015 | C/A | Not Available | ||||
| rs2235048 | G/A | Not Available | ||||
| rs3789243 | G/A | Not Available | ||||
| rs3842 | T/C | Not Available | ||||
| rs72552784 | ABCB1: c.2995G>A, c.2995G>A, g.201651G>A, g.25178757C>T, mRNA 3413G>A, p.Ala999Thr | G > A | Missense | Ala999Thr | ||
| rs9282564 | ABCB1: c.61A>G, c.61A>C, c.61A>G, c.61A>T, g.118125A>C, g.118125A>G, g.118125A>T, g.25262283T>A, g.25262283T>C, g.25262283T>G, mRNA 479A>G, p.Asn21Asp, p.Asn21His, p.Asn21Tyr | T > C | Missense | Asn21Asp |
Overview
| Alternate Names: | ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 1; ABCB1; ATP-binding cassette sub-family B member 1; ATP-binding cassette, subfamily B, member 1; DOXORUBICIN RESISTANCE; Homo sapiens ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1), mRNA.; P glycoprotein 1; P glycoprotein 1/multiple drug resistance 1; P-GLYCOPROTEIN 1; PGY1; P-glycoprotein 1; P-glycoprotein-1/multiple drug resistance-1; colchicin sensitivity; doxorubicin resistance; multidrug resistance 1; multidrug resistance protein 1 |
|---|---|
| Alternate Symbols: | ABC20; ABCB1; CD243; CLCS; GP170; MDR1; MGC163296; NM_000927.1; P-GP; P-gp; PGY1 |
| Haplotypes: | ABCB1*1; ABCB1*13; ABCB1*13 (per Kroetz et al. 2003 [PMID: 12893986]); ABCB1*2 (per Kim et al. 2001 [PMID: 11503014]); ABCB1*2 (per Kroetz et al. 2003 [PMID: 12893986]) |
| PharmGKB Accession Id: | PA267 |
Details
| Cytogenetic Location: | chr7 : q21.12 - q21.12 |
|---|---|
| GP mRNA Boundary†: | chr7 : 87132948 - 87342564 |
| GP Gene Boundary†: | chr7 : 87129948 - 87352564 |
| Strand: | minus |
| Product Name: | ATP-binding cassette sub-family B member 1, P glycoprotein 1, colchicin sensitivity, doxorubicin resistance, multidrug resistance 1 |
All alleles are displayed on the positive chromosomal strand.
| Haplotype | rs10276036 | rs1045642 | rs1128503 | rs2032582 | rs2235013 | rs2235033 |
|---|---|---|---|---|---|---|
| ABCB1*1 | C | G | G | C | C | A |
| ABCB1*13 | T | A | A | A | T | G |
| ABCB1*13 (per Kroetz et al. 2003 [PMID: 12893986]) | T | A | A | A | T | G |
| ABCB1*2 (per Kim et al. 2001 [PMID: 11503014]) | C | A | A | A | C | A |
| ABCB1*2 (per Kroetz et al. 2003 [PMID: 12893986]) | C | A | G | C | C | A |
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
-
Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
-
Citalopram Pathway, Pharmacokinetics
Pharmacokinetics of the selective serotonin reuptake inhibitor citalopram.
-
Clopidogrel Pathway, Pharmacokinetics
Clopidogrel metabolism.
-
Codeine and Morphine Pathway, Pharmacokinetics
Representation of the candidate genes involved in metabolism of codeine and morphine.
-
Doxorubicin Pathway (Cancer Cell), Pharmacodynamics
Representation of the candidate genes involved in the action of doxorubicin in a stylized cancer cell.
-
Doxorubicin Pathway, Pharmacokinetics
Diagrammatic representation of the transport and metabolism of doxorubicin.
-
Erlotinib Pathway, Pharmacokinetics
Model human liver cell showing genes involved in the transportation and metabolism of Erlotinib.
-
Etoposide Pathway
Etoposide cellular disposition and effects.
-
Gefitinib Pathway (PK)
Representation of the candidate genes involved in the transportation and metabolism of gefitinib
-
Irinotecan Pathway, Pharmacodynamics
Model non-tissue specific cancer cell displaying genes which may be involved in the irinotecan pathway.
-
Irinotecan Pathway, Pharmacokinetics
Model human liver cell showing blood, bile and intestinal compartments, indicating tissue specific involvement of genes in the irinotecan pathway.
-
Lamivudine Pathway, Pharmacokinetics/Pharmacodynamics
Representation of candidate genes involved in the metabolism of lamivudine and its mechanism of antiviral action.
-
Methotrexate Pathway
Methotrexate cellular disposition and effects
-
Methotrexate Pathway (Brain Cell), Pharmacokinetics
Representation of transport and exchange of methotrexate in the brain.
-
Methotrexate Pathway, Pharmacokinetics
Diagramatic representation of uptake, transport and elimination of methotrexate.
-
Pravastatin Pathway, Pharmacokinetics
Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
-
Proton Pump Inhibitor Pathway, Pharmacokinetics
Omeprazole metabolism in the liver.
-
Statin Pathway - Generalized, Pharmacokinetics
Representation of the superset of all genes involved in the transport, metabolism and clearance of statin class drugs.
-
Statin Pathway, Pharmacodynamics
Genes involved in mediating statin effects on hepatic cholesterol metabolism and consequent effects on plasma lipoprotein transport.
-
Taxane Pathway
Representation of the genes involved in the metabolism and transport of paclitaxel and docetaxel, and the downstream effects of the drugs
-
Vinka Alkaloid Pathway, Pharmacokinetics
Representation of the genes involved in the metabolism, transport, and downstream effects of the vinca alkaloid vincristine.
-
Warfarin Pathway, Pharmacokinetics
Representation of the candidate genes involved in transport, metabolism and clearance of warfarin.
-
Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics
Representation of candidate genes involved in the metabolism of zidovudine and its mechanism of antiviral action.
External Pathways
Links to non-PharmGKB pathways.
Datasets
- ABCB1 Functional Protein Variants
- Folate pathway gene expression and methotrexate pharmacodynamics
- G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression.
- Hepatic CYP3A4 mRNA expression (Cohort III)
- Hepatic CYP3A4 Protein Expression and Midazolam Hydroxylation (Cohort II)
- Hepatic CYP3A5 predicts Saquinavir clearance
- Intestinal CYP3A4 Protein Expression (Cohort IV)
- Intestinal Midazolam Hydroxylase Activity (Cohort V)
- Irinotecan Clinical Data
- Midazolam and docetaxel clearance
- Patient responses to tamoxifen
- Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia
- Pharmacokinetics of etoposide, catechol metabolite
- Pharmacokinetics of irinotecan in cancer patients
- Protein expression of genes in the irinotecan pathway
- RNA expression in metabolite and transport genes
- Tacrolimus dosing and outcome in lung transplant patients
- Tacrolimus dosing and Steroid Weaning in pediatric heart transplant patients
- Testosterone 6beta-hydroxylation Activity Induced by Rifampin (Cohort I)
- Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of CYP3A5
- A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871
- ABCB1 Cellular Phenotype Results for 3 Variant Sites (+89A>T, +146G>A and +193A>G)
- ABCB1 Cellular Phenotype Results for 9 Variant Sites (N21D, S400T, R669C,?)
- Coexpression of MDR1 variants in CHO cells has no effect on baseline IKr amplitude
- Drug resistance of nine ABCB1 polymorphisms
- Functional SNPs in ABCB1 Polymorphisms
- Genetic Variants in Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) associated Adverse Effects and Response to Therapy
- Genetic Variants in Selective Serotonin Reuptake Inhibitors (SSRIs) associated Adverse Events
- Genetic Variants in Tricyclic Antidepressant associated Adverse Events
- Pharmacogenetics of Minimal Residual Disease Response in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group
- PMT06_044.xml
- Resistance Levels of Nine ABCB1 Variants to Four Drugs
Downloads
You must sign in before you can download data.
LinkOuts
- UniProtKB:
- A4D1D2_HUMAN (A4D1D2)
- MDR1_HUMAN (P08183)
- Ensembl:
- ENSG00000085563
- GenAtlas:
- ABCB1
- GeneCard:
- GC07M087132 (5243)
- SOURCE:
- ABCB1
- MutDB:
- ABCB1
Common Searches
Non-Curated Publications
A list of non-curated publications that mention this gene is available.